# Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease

> **NCT00481520** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 72 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** SAM-531
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00481520
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2009-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481520, "Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00481520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*